Ketoreductase ChKRED12 catalyzes the asymmetric bioreduction of ethyl 3-oxo-3-(2-thienyl) propanoate to produce the key chiral intermediate of duloxetine. To improve the robustness of the enzyme, we used the FireProt web server to predict potential thermostabilizing amino acid substitutions, and we experimentally confirmed 4 beneficial substitutions (S79P, L128M, V162I and G163A). These substitutions were combined to form a quadruple mutant (M7234), which displayed substantially enhanced thermostability with half-life of inactivation increased to 58 h at 45 °C, approximately 21-fold of that of the wild-type. Moreover, the temperature optimum increased to 45 °C, which is 5 °C higher than that of the wild-type. M7234 was able to catalyze the complete conversion of 100 g/L substrate within 8 h and produce (S)-3-hydroxy-3-(2-thienyl) propanoate at >99% ee, achieving a space-time yield of 289 g/L/d after column chromatography.
Read full abstract